Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Cancer therapy with major histocompatibility complex-deficient and interferon β-producing myeloid cells derived from allogeneic embryonic stem cells.

Umemoto S, Haruta M, Sakisaka M, Ikeda T, Tsukamoto H, Komohara Y, Takeya M, Nishimura Y, Senju S.

Cancer Sci. 2019 Jul 26. doi: 10.1111/cas.14144. [Epub ahead of print]

2.

Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3.

Okada M, Tada Y, Seki T, Tohyama S, Fujita J, Suzuki T, Shimomura M, Ofuji K, Kishino Y, Nakajima K, Tanosaki S, Someya S, Kanazawa H, Senju S, Nakatsura T, Fukuda K.

Biochem Biophys Res Commun. 2019 Apr 9;511(3):711-717. doi: 10.1016/j.bbrc.2019.02.094. Epub 2019 Mar 1.

PMID:
30827508
3.

Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cell-derived myelomonocytic cells producing interferon beta.

Imamura Y, Tashiro H, Tsend-Ayush G, Haruta M, Dashdemberel N, Komohara Y, Tsuboki J, Takaishi K, Ohba T, Nishimura Y, Katabuchi H, Senju S.

Cancer Sci. 2018 Nov;109(11):3403-3410. doi: 10.1111/cas.13775. Epub 2018 Oct 24.

4.

iPS cell serves as a source of dendritic cells for in vitro dengue virus infection model.

Manh DH, Mizukami S, Dumre SP, Raekiansyah M, Senju S, Nishimura Y, Karbwang J, Huy NT, Morita K, Hirayama K.

J Gen Virol. 2018 Sep;99(9):1239-1247. doi: 10.1099/jgv.0.001119. Epub 2018 Jul 30.

PMID:
30058991
5.

Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.

Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, Senju S, Ihn H, Nishimura Y, Oshiumi H.

Cancer Res. 2018 Sep 1;78(17):5011-5022. doi: 10.1158/0008-5472.CAN-18-0118. Epub 2018 Jul 2.

6.

Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response.

Ueda N, Uemura Y, Zhang R, Kitayama S, Iriguchi S, Kawai Y, Yasui Y, Tatsumi M, Ueda T, Liu TY, Mizoro Y, Okada C, Watanabe A, Nakanishi M, Senju S, Nishimura Y, Kuzushima K, Kiyoi H, Naoe T, Kaneko S.

Stem Cell Reports. 2018 Jun 5;10(6):1935-1946. doi: 10.1016/j.stemcr.2018.04.025. Epub 2018 May 24.

7.

Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro.

Tsuruta M, Ueda S, Yew PY, Fukuda I, Yoshimura S, Kishi H, Hamana H, Hirayama M, Yatsuda J, Irie A, Senju S, Yuba E, Kamba T, Eto M, Nakayama H, Nishimura Y.

Oncoimmunology. 2018 Jan 5;7(4):e1415687. doi: 10.1080/2162402X.2017.1415687. eCollection 2018.

8.

Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity.

Tsukamoto H, Fujieda K, Senju S, Ikeda T, Oshiumi H, Nishimura Y.

Cancer Sci. 2018 Mar;109(3):523-530. doi: 10.1111/cas.13433. Epub 2017 Nov 16. Review.

9.

Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin.

Suenaga G, Ikeda T, Masuda T, Motokawa H, Yamashita T, Takamatsu K, Misumi Y, Ueda M, Matsui H, Senju S, Ando Y.

Sci Rep. 2017 May 8;7(1):1579. doi: 10.1038/s41598-017-01775-4.

10.

Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression.

Tsukamoto H, Fujieda K, Hirayama M, Ikeda T, Yuno A, Matsumura K, Fukuma D, Araki K, Mizuta H, Nakayama H, Senju S, Nishimura Y.

Cancer Res. 2017 May 1;77(9):2279-2291. doi: 10.1158/0008-5472.CAN-16-2446. Epub 2017 Feb 24.

11.

Therapy of primary and metastatic liver cancer by human iPS cell-derived myeloid cells producing interferon-β.

Sakisaka M, Haruta M, Komohara Y, Umemoto S, Matsumura K, Ikeda T, Takeya M, Inomata Y, Nishimura Y, Senju S.

J Hepatobiliary Pancreat Sci. 2017 Feb;24(2):109-119. doi: 10.1002/jhbp.422. Epub 2017 Feb 8.

PMID:
28008721
12.

Novel Antibody for the Treatment of Transthyretin Amyloidosis.

Hosoi A, Su Y, Torikai M, Jono H, Ishikawa D, Soejima K, Higuchi H, Guo J, Ueda M, Suenaga G, Motokawa H, Ikeda T, Senju S, Nakashima T, Ando Y.

J Biol Chem. 2016 Nov 25;291(48):25096-25105. Epub 2016 Oct 7.

13.

Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment.

Suenaga G, Ikeda T, Komohara Y, Takamatsu K, Kakuma T, Tasaki M, Misumi Y, Ueda M, Ito T, Senju S, Ando Y.

PLoS One. 2016 Oct 3;11(10):e0163944. doi: 10.1371/journal.pone.0163944. eCollection 2016.

14.

iPS-cell derived dendritic cells and macrophages for cancer therapy.

Senju S.

Rinsho Ketsueki. 2016 Aug;57(8):1074-9. doi: 10.11406/rinketsu.57.1074. Japanese.

PMID:
27599426
15.

Transient Mild Cerebral Ischemia Significantly Deteriorated Cognitive Impairment in a Mouse Model of Alzheimer's Disease via Angiotensin AT1 Receptor.

Nakagawa T, Hasegawa Y, Uekawa K, Senju S, Nakagata N, Matsui K, Kim-Mitsuyama S.

Am J Hypertens. 2017 Feb;30(2):141-150. doi: 10.1093/ajh/hpw099. Epub 2016 Aug 29.

PMID:
27572961
16.

An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs.

Hirayama M, Tomita Y, Yuno A, Tsukamoto H, Senju S, Imamura Y, Sayem MA, Irie A, Yoshitake Y, Fukuma D, Shinohara M, Hamada A, Jono H, Yuba E, Kono K, Yoshida K, Tsunoda T, Nakayama H, Nishimura Y.

Oncoimmunology. 2016 Jan 4;5(6):e1123368. doi: 10.1080/2162402X.2015.1123368. eCollection 2016 Jun.

17.

BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells.

Ueda N, Zhang R, Tatsumi M, Liu TY, Kitayama S, Yasui Y, Sugai S, Iwama T, Senju S, Okada S, Nakatsura T, Kuzushima K, Kiyoi H, Naoe T, Kaneko S, Uemura Y.

Cell Mol Immunol. 2018 Jan;15(1):15-26. doi: 10.1038/cmi.2016.7. Epub 2016 May 15.

18.

Intracerebroventricular Infusion of Angiotensin-(1-7) Ameliorates Cognitive Impairment and Memory Dysfunction in a Mouse Model of Alzheimer's Disease.

Uekawa K, Hasegawa Y, Senju S, Nakagata N, Ma M, Nakagawa T, Koibuchi N, Kim-Mitsuyama S.

J Alzheimers Dis. 2016 Apr 23;53(1):127-33. doi: 10.3233/JAD-150642.

PMID:
27128367
19.

Generation of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML Technology.

Imamura Y, Haruta M, Tomita Y, Matsumura K, Ikeda T, Yuno A, Hirayama M, Nakayama H, Mizuta H, Nishimura Y, Senju S.

PLoS One. 2016 Apr 6;11(4):e0152384. doi: 10.1371/journal.pone.0152384. eCollection 2016.

20.

Identification of glypican-3-derived long peptides activating both CD8+ and CD4+ T cells; prolonged overall survival in cancer patients with Th cell response.

Sayem MA, Tomita Y, Yuno A, Hirayama M, Irie A, Tsukamoto H, Senju S, Yuba E, Yoshikawa T, Kono K, Nakatsura T, Nishimura Y.

Oncoimmunology. 2015 Aug 31;5(1):e1062209. eCollection 2016.

21.

Immunotherapy against Metastatic Melanoma with Human iPS Cell-Derived Myeloid Cell Lines Producing Type I Interferons.

Miyashita A, Fukushima S, Nakahara S, Kubo Y, Tokuzumi A, Yamashita J, Aoi J, Haruta M, Senju S, Nishimura Y, Jinnin M, Ihn H.

Cancer Immunol Res. 2016 Mar;4(3):248-58. doi: 10.1158/2326-6066.CIR-15-0096. Epub 2015 Dec 29.

22.

IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age.

Tsukamoto H, Senju S, Matsumura K, Swain SL, Nishimura Y.

Nat Commun. 2015 Apr 7;6:6702. doi: 10.1038/ncomms7702.

23.

Generation of mouse pluripotent stem cell-derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells.

Zhang R, Liu TY, Senju S, Haruta M, Hirosawa N, Suzuki M, Tatsumi M, Ueda N, Maki H, Nakatsuka R, Matsuoka Y, Sasaki Y, Tsuzuki S, Nakanishi H, Araki R, Abe M, Akatsuka Y, Sakamoto Y, Sonoda Y, Nishimura Y, Kuzushima K, Uemura Y.

Cancer Immunol Res. 2015 Jun;3(6):668-77. doi: 10.1158/2326-6066.CIR-14-0117. Epub 2015 Feb 11.

24.

Suppression of Th1-mediated autoimmunity by embryonic stem cell-derived dendritic cells.

Ikeda T, Hirata S, Takamatsu K, Haruta M, Tsukamoto H, Ito T, Uchino M, Ando Y, Nagafuchi S, Nishimura Y, Senju S.

PLoS One. 2014 Dec 18;9(12):e115198. doi: 10.1371/journal.pone.0115198. eCollection 2014.

25.

Degradation of amyloid beta by human induced pluripotent stem cell-derived macrophages expressing Neprilysin-2.

Takamatsu K, Ikeda T, Haruta M, Matsumura K, Ogi Y, Nakagata N, Uchino M, Ando Y, Nishimura Y, Senju S.

Stem Cell Res. 2014 Nov;13(3 Pt A):442-53. doi: 10.1016/j.scr.2014.10.001. Epub 2014 Oct 12.

26.

Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease.

Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Imamura Y, Yatsuda J, Sayem MA, Irie A, Hamada A, Jono H, Yoshida K, Tsunoda T, Daigo Y, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y.

Oncoimmunology. 2014 Mar 27;3:e28100. eCollection 2014.

27.

RNA function. Ribosome stalling induced by mutation of a CNS-specific tRNA causes neurodegeneration.

Ishimura R, Nagy G, Dotu I, Zhou H, Yang XL, Schimmel P, Senju S, Nishimura Y, Chuang JH, Ackerman SL.

Science. 2014 Jul 25;345(6195):455-9. doi: 10.1126/science.1249749.

28.

Therapy of peritoneally disseminated colon cancer by TAP-deficient embryonic stem cell-derived macrophages in allogeneic recipients.

Haga E, Endo Y, Haruta M, Koba C, Matsumura K, Takamatsu K, Ikeda T, Nishimura Y, Senju S.

J Immunol. 2014 Aug 15;193(4):2024-33. doi: 10.4049/jimmunol.1303473. Epub 2014 Jul 16.

29.

Application of iPS cell-derived macrophages to cancer therapy.

Senju S, Koba C, Haruta M, Matsunaga Y, Matsumura K, Haga E, Sasaki Y, Ikeda T, Takamatsu K, Nishimura Y.

Oncoimmunology. 2014 Jan 1;3(1):e27927. Epub 2014 Feb 14.

30.

Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression.

Tsukamoto H, Nishikata R, Senju S, Nishimura Y.

Cancer Immunol Res. 2013 Jul;1(1):64-76. doi: 10.1158/2326-6066.CIR-13-0030. Epub 2013 Apr 29.

31.

Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients.

Tomita Y, Yuno A, Tsukamoto H, Senju S, Yoshimura S, Osawa R, Kuroda Y, Hirayama M, Irie A, Hamada A, Jono H, Yoshida K, Tsunoda T, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y.

Int J Cancer. 2014 Jan 15;134(2):352-66.

32.

Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens.

Yatsuda J, Irie A, Harada K, Michibata Y, Tsukamoto H, Senju S, Tomita Y, Yuno A, Hirayama M, Abu Sayem M, Takeda N, Shibuya I, Sogo S, Fujiki F, Sugiyama H, Eto M, Nishimura Y.

PLoS One. 2013 Dec 30;8(12):e84908. doi: 10.1371/journal.pone.0084908. eCollection 2013.

33.

Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models.

Koba C, Haruta M, Matsunaga Y, Matsumura K, Haga E, Sasaki Y, Ikeda T, Takamatsu K, Nishimura Y, Senju S.

PLoS One. 2013 Jun 24;8(6):e67567. doi: 10.1371/journal.pone.0067567. Print 2013.

34.

Generation of a large number of functional dendritic cells from human monocytes expanded by forced expression of cMYC plus BMI1.

Haruta M, Tomita Y, Imamura Y, Matsumura K, Ikeda T, Takamatsu K, Nishimura Y, Senju S.

Hum Immunol. 2013 Oct;74(10):1400-8. doi: 10.1016/j.humimm.2013.05.017. Epub 2013 Jun 26.

PMID:
23811433
35.

Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.

Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Irie A, Kawahara K, Yatsuda J, Hamada A, Jono H, Yoshida K, Tsunoda T, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y.

Clin Cancer Res. 2013 Aug 15;19(16):4508-20. doi: 10.1158/1078-0432.CCR-13-0197. Epub 2013 May 28.

36.

TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells.

Haruta M, Tomita Y, Yuno A, Matsumura K, Ikeda T, Takamatsu K, Haga E, Koba C, Nishimura Y, Senju S.

Gene Ther. 2013 May;20(5):504-13. doi: 10.1038/gt.2012.59. Epub 2012 Aug 9.

PMID:
22875043
37.

[Cancer immunotherapy by utilizing dedritic cells derived from pluripotent stem cells].

Fukushima S, Ihn H, Nishimura Y, Senju S.

Nihon Rinsho Meneki Gakkai Kaishi. 2011;34(3):113-20. Review. Japanese.

38.

Modulation of exosome-mediated mRNA turnover by interaction of GTP-binding protein 1 (GTPBP1) with its target mRNAs.

Woo KC, Kim TD, Lee KH, Kim DY, Kim S, Lee HR, Kang HJ, Chung SJ, Senju S, Nishimura Y, Kim KT.

FASEB J. 2011 Aug;25(8):2757-69. doi: 10.1096/fj.10-178715. Epub 2011 Apr 22.

PMID:
21515746
39.

Immunotherapy with pluripotent stem cell-derived dendritic cells.

Senju S, Matsunaga Y, Fukushima S, Hirata S, Motomura Y, Fukuma D, Matsuyoshi H, Nishimura Y.

Semin Immunopathol. 2011 Nov;33(6):603-12. doi: 10.1007/s00281-011-0263-y. Epub 2011 Apr 5. Review.

PMID:
21461992
40.

Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy.

Senju S, Haruta M, Matsumura K, Matsunaga Y, Fukushima S, Ikeda T, Takamatsu K, Irie A, Nishimura Y.

Gene Ther. 2011 Sep;18(9):874-83. doi: 10.1038/gt.2011.22. Epub 2011 Mar 24.

PMID:
21430784
41.

A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.

Tomita Y, Imai K, Senju S, Irie A, Inoue M, Hayashida Y, Shiraishi K, Mori T, Daigo Y, Tsunoda T, Ito T, Nomori H, Nakamura Y, Kohrogi H, Nishimura Y.

Cancer Sci. 2011 Apr;102(4):697-705. doi: 10.1111/j.1349-7006.2011.01865.x. Epub 2011 Feb 10.

42.

Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer.

Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, Nakagawa H, Nakamura Y, Baba H, Nishimura Y.

Br J Cancer. 2011 Jan 18;104(2):300-7. doi: 10.1038/sj.bjc.6606052. Epub 2010 Dec 21.

43.

[Establishment of pluripotent stem cell-derived dendritic cells for clinical application].

Senju S.

Rinsho Ketsueki. 2010 Nov;51(11):1668-73. Review. Japanese. No abstract available.

PMID:
21157130
44.

Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells.

Tomita Y, Harao M, Senju S, Imai K, Hirata S, Irie A, Inoue M, Hayashida Y, Yoshimoto K, Shiraishi K, Mori T, Nomori H, Kohrogi H, Nishimura Y.

Cancer Sci. 2011 Jan;102(1):71-8. doi: 10.1111/j.1349-7006.2010.01780.x. Epub 2010 Nov 19.

45.

Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells.

Ikeda T, Hirata S, Fukushima S, Matsunaga Y, Ito T, Uchino M, Nishimura Y, Senju S.

J Immunol. 2010 Nov 1;185(9):5259-67. doi: 10.4049/jimmunol.0902797. Epub 2010 Oct 4.

46.

Pluripotent stem cell-derived dendritic cells for immunotherapy.

Senju S, Matsunaga Y, Fukushima S, Hirata S, Matsuyoshi H, Nishimura Y.

Front Biosci (Elite Ed). 2010 Jun 1;2:1520-7. Review.

PMID:
20515823
47.

Bisphenol A in combination with TNF-alpha selectively induces Th2 cell-promoting dendritic cells in vitro with an estrogen-like activity.

Guo H, Liu T, Uemura Y, Jiao S, Wang D, Lin Z, Narita Y, Suzuki M, Hirosawa N, Ichihara Y, Ishihara O, Kikuchi H, Sakamoto Y, Senju S, Zhang Q, Ling F.

Cell Mol Immunol. 2010 May;7(3):227-34. doi: 10.1038/cmi.2010.14. Epub 2010 Apr 12.

48.

Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant.

Chen YZ, Liu G, Senju S, Wang Q, Irie A, Haruta M, Matsui M, Yasui F, Kohara M, Nishimura Y.

Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):165-77.

PMID:
20378004
49.

Pluripotent stem cells as source of dendritic cells for immune therapy.

Senju S, Hirata S, Motomura Y, Fukuma D, Matsunaga Y, Fukushima S, Matsuyoshi H, Nishimura Y.

Int J Hematol. 2010 Apr;91(3):392-400. doi: 10.1007/s12185-010-0520-1. Epub 2010 Feb 13. Review.

PMID:
20155337
50.

Identification of SPARC as a candidate target antigen for immunotherapy of various cancers.

Inoue M, Senju S, Hirata S, Ikuta Y, Hayashida Y, Irie A, Harao M, Imai K, Tomita Y, Tsunoda T, Furukawa Y, Ito T, Nakamura Y, Baba H, Nishimura Y.

Int J Cancer. 2010 Sep 1;127(6):1393-403. doi: 10.1002/ijc.25160.

Supplemental Content

Support Center